ImClone Systems
ImClone Systems Incorporated is a biopharmaceutical company dedicated to developing biologic medicines in the area of oncology. It was founded in 1984 and is headquartered in New York City. On October 6, 2008, it accepted a $6.5 billion acquisition offer from Eli Lilly and Company, and became a fully owned subsidiary of Eli Lilly and Company on November 24, 2008. Prior to the acquisition, it was traded on the NASDAQ stock exchange under the symbol IMCL.
Read more about ImClone Systems: Insider Trading Scandal, Compassionate Use Controversy, Carl Icahn Acquisition, Takeover Offer From Bristol-Myers Squibb, and Subsequent Bidding Showdown, Yeda/Aventis/Imclone Patent Dispute
Famous quotes containing the word systems:
“We have done scant justice to the reasonableness of cannibalism. There are in fact so many and such excellent motives possible to it that mankind has never been able to fit all of them into one universal scheme, and has accordingly contrived various diverse and contradictory systems the better to display its virtues.”
—Ruth Benedict (1887–1948)